Frequently asked questions How long do body aches last on a GLP-1 medication
Disclosures: Shirley Bong: Nothing to Disclose, Calvin Koh: Nothing to Disclose, Jonathan Lee: Nothing to Disclose, Mark Muthiah: Lerna Bio: Stock privately held company, Olympus: Speaking and Teaching, Boston Scientific: Speaking and Teaching, Novo Nordisk: Grant/Research Support, Echosens: Grant/Research Support, Gilead: Advisor, Guan Huei Lee: Nothing to Disclose, Lin Liu: Nothing to Disclose, Yin Mei Lee: Nothing to Disclose 1675 LIVER CIRRHOSIS AND ITS IMPACT ON CLINICAL OUTCOMES IN ADULT RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA: A RETROSPECTIVE ANALYSIS OF THE NATIONAL INPATIENT SAMPLE Raghav Bassi 1 Zubair Bodla 2 Mariam Hashmi 2 Fatima Niaz 3 Muhammad Khalil 4 Yaseen Perbtani 2 Tony Brar 2 , 1 University of Central Florida College of Medicine, 2 University of Central Florida, 3 King Edward Medical University, 4 University of Alabama Background: Respiratory syncytial virus (RSV) pneumonia is a significant cause of mortality, especially among adults with underlying comorbidities
In sum, the GLP-1 phenomenon has reshaped pharma manufacturing strategy: it has accelerated vertical integration (Catalent deal), expanded global CDMO networks, and spurred forward-looking plant designs
Experienced lifters may primarily maintain rather than gain muscle
GLP-1 is commonly described in research literature as a 30- or 31-amino acid peptide derived from proglucagon
